{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:56Z","timestamp":1761894596573},"reference-count":9,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,12,15]]},"abstract":"<jats:p>In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR.<\/jats:p>","DOI":"10.1182\/blood-2007-07-104091","type":"journal-article","created":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T00:40:04Z","timestamp":1191285604000},"page":"4172-4174","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival"],"prefix":"10.1182","volume":"110","author":[{"given":"Michelle A.","family":"Elliott","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis L.","family":"Letendre","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Wolf","sequence":"additional","affiliation":[{"name":"Pharmacy Services, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111812335095600_B1","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.[see comment].","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"2019111812335095600_B2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","article-title":"A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.","volume":"107","author":"Wheatley","year":"1999","journal-title":"Br J Haematol"},{"key":"2019111812335095600_B3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MOH.0b013e32801684c7","article-title":"Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.","volume":"14","author":"Mr\u00f3zek","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"2019111812335095600_B4","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood.V86.4.1292.bloodjournal8641292","article-title":"Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia.","volume":"86","author":"Gajjar","year":"1995","journal-title":"Blood"},{"key":"2019111812335095600_B5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1996.14.8.2403","article-title":"Cytoreduction and prognosis in childhood acute lymphoblastic leukemia.[see comment][comment].","volume":"14","author":"Schrappe","year":"1996","journal-title":"J Clin Oncol"},{"key":"2019111812335095600_B6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood.V95.1.72","article-title":"Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.","volume":"95","author":"Estey","year":"2000","journal-title":"Blood"},{"key":"2019111812335095600_B7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.[see comment].","volume":"101","author":"Kern","year":"2003","journal-title":"Blood"},{"key":"2019111812335095600_B8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V56.3.361.bloodjournal563361","article-title":"Prediction of response to chemotherapy in acute myelocytic leukemia.","volume":"56","author":"Preisler","year":"1980","journal-title":"Blood"},{"key":"2019111812335095600_B9","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/13\/4172\/1218899\/zh802407004172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/13\/4172\/1218899\/zh802407004172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T17:37:34Z","timestamp":1574098654000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/13\/4172\/103202\/Early-peripheral-blood-blast-clearance-during"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,15]]},"references-count":9,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2007,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-104091","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,15]]}}}